ASCO 2021 | Genitourinary cancer trial updates at ASCO 2021

Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares highlights on the latest genitourinary updates presented at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting, such as the Phase III JAVELIN Bladder 100 trial (NCT02603432). The trial evaluates the efficacy of avelumab, a PD-L1 inhibitor, as maintenance therapy in pre-treated patients with locally advanced or metastatic urothelial cancer. The results indicate patients receiving maintenance therapy with avelumab fared better than those without receiving avelumab. This interview took place at the ASCO 2021 Virtual Meeting.